Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

93 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review.
Prelaj A, Miskovic V, Zanitti M, Trovo F, Genova C, Viscardi G, Rebuzzi SE, Mazzeo L, Provenzano L, Kosta S, Favali M, Spagnoletti A, Castelo-Branco L, Dolezal J, Pearson AT, Lo Russo G, Proto C, Ganzinelli M, Giani C, Ambrosini E, Turajlic S, Au L, Koopman M, Delaloge S, Kather JN, de Braud F, Garassino MC, Pentheroudakis G, Spencer C, Pedrocchi ALG. Prelaj A, et al. Among authors: viscardi g. Ann Oncol. 2024 Jan;35(1):29-65. doi: 10.1016/j.annonc.2023.10.125. Epub 2023 Oct 23. Ann Oncol. 2024. PMID: 37879443 Review.
Implication of the Hedgehog pathway in hepatocellular carcinoma.
Della Corte CM, Viscardi G, Papaccio F, Esposito G, Martini G, Ciardiello D, Martinelli E, Ciardiello F, Morgillo F. Della Corte CM, et al. Among authors: viscardi g. World J Gastroenterol. 2017 Jun 28;23(24):4330-4340. doi: 10.3748/wjg.v23.i24.4330. World J Gastroenterol. 2017. PMID: 28706416 Free PMC article. Review.
HGF/MET and the Immune System: Relevance for Cancer Immunotherapy.
Papaccio F, Della Corte CM, Viscardi G, Di Liello R, Esposito G, Sparano F, Ciardiello F, Morgillo F. Papaccio F, et al. Among authors: viscardi g. Int J Mol Sci. 2018 Nov 14;19(11):3595. doi: 10.3390/ijms19113595. Int J Mol Sci. 2018. PMID: 30441809 Free PMC article. Review.
EPSILoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation Cohort.
Prelaj A, Ferrara R, Rebuzzi SE, Proto C, Signorelli D, Galli G, De Toma A, Randon G, Pagani F, Viscardi G, Brambilla M, Trevisan B, Ganzinelli M, Martinetti A, Gallucci R, Di Mauro RM, Molino G, Zilembo N, Torri V, de Braud FM, Garassino MC, Lo Russo G. Prelaj A, et al. Among authors: viscardi g. Cancers (Basel). 2019 Dec 5;11(12):1954. doi: 10.3390/cancers11121954. Cancers (Basel). 2019. PMID: 31817541 Free PMC article.
Integrating clinical and biological prognostic biomarkers in patients with advanced NSCLC treated with immunotherapy: the DEMo score system.
Prelaj A, Proto C, Lo Russo G, Signorelli D, Ferrara R, Mensah M, Galli G, De Toma A, Viscardi G, Brambilla M, Lobefaro R, Trevisan B, Trovò F, Torri V, Sozzi G, Garassino MC, Boeri M. Prelaj A, et al. Among authors: viscardi g. Transl Lung Cancer Res. 2020 Jun;9(3):617-628. doi: 10.21037/tlcr-20-231. Transl Lung Cancer Res. 2020. PMID: 32676324 Free PMC article.
Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers.
Lobefaro R, Viscardi G, Di Liello R, Massa G, Iacovino ML, Sparano F, Della Corte CM, Ferrara R, Signorelli D, Proto C, Prelaj A, Galli G, De Toma A, Brambilla M, Ganzinelli M, Trevisan B, Ciardiello F, De Braud F, Morgillo F, Garassino MC, Lo Russo G. Lobefaro R, et al. Among authors: viscardi g. Lung Cancer. 2021 Feb;152:165-173. doi: 10.1016/j.lungcan.2020.12.027. Epub 2020 Dec 28. Lung Cancer. 2021. PMID: 33421923
Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program.
Prelaj A, Bottiglieri A, Proto C, Lo Russo G, Signorelli D, Ferrara R, Galli G, De Toma A, Viscardi G, Brambilla M, Lobefaro R, Nichetti F, Manglaviti S, Occhipinti M, Labianca A, Ganzinelli M, Gallucci R, Zilembo N, Greco GF, Torri V, de Braud F, Garassino MC. Prelaj A, et al. Among authors: viscardi g. Eur J Cancer. 2021 May;149:235-248. doi: 10.1016/j.ejca.2021.02.038. Epub 2021 Apr 2. Eur J Cancer. 2021. PMID: 33820681
Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology.
Manglaviti S, Brambilla M, Signorelli D, Ferrara R, Lo Russo G, Proto C, Galli G, De Toma A, Occhipinti M, Viscardi G, Beninato T, Zattarin E, Bini M, Lobefaro R, Massa G, Bottiglieri A, Apollonio G, Sottotetti E, Di Mauro RM, Trevisan B, Ganzinelli M, Fabbri A, de Braud FGM, Garassino MC, Prelaj A. Manglaviti S, et al. Among authors: viscardi g. Clin Lung Cancer. 2022 Jan;23(1):e17-e28. doi: 10.1016/j.cllc.2021.06.013. Epub 2021 Jul 5. Clin Lung Cancer. 2022. PMID: 34334296
Circulating CD81-expressing extracellular vesicles as biomarkers of response for immune-checkpoint inhibitors in advanced NSCLC.
Signorelli D, Ghidotti P, Proto C, Brambilla M, De Toma A, Ferrara R, Galli G, Ganzinelli M, Lo Russo G, Prelaj A, Occhipinti M, Viscardi G, Capizzuto V, Pontis F, Petraroia I, Ferretti AM, Colombo MP, Torri V, Sozzi G, Garassino MC, Jachetti E, Fortunato O. Signorelli D, et al. Among authors: viscardi g. Front Immunol. 2022 Sep 20;13:987639. doi: 10.3389/fimmu.2022.987639. eCollection 2022. Front Immunol. 2022. PMID: 36203609 Free PMC article.
Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis.
Viscardi G, Tralongo AC, Massari F, Lambertini M, Mollica V, Rizzo A, Comito F, Di Liello R, Alfieri S, Imbimbo M, Della Corte CM, Morgillo F, Simeon V, Lo Russo G, Proto C, Prelaj A, De Toma A, Galli G, Signorelli D, Ciardiello F, Remon J, Chaput N, Besse B, de Braud F, Garassino MC, Torri V, Cinquini M, Ferrara R. Viscardi G, et al. Eur J Cancer. 2022 Dec;177:175-185. doi: 10.1016/j.ejca.2022.09.031. Epub 2022 Oct 5. Eur J Cancer. 2022. PMID: 36368251 Review.
93 results